Madrigal to Present New Data from the Company’s MASH Program at EASL 2026 Demonstrating the Effects of Rezdiffra on Markers of Cardiovascular and Portal Hypertension Risk
Madrigal Pharmaceuticals will present multiple abstracts at the EASL Congress 2026, highlighting secondary analyses from its pivotal Phase 3 MAESTRO-NASH and MAESTRO-NAFLD-1 trials. The data demonstrates improvements in cardiovascular risk markers, including Lp(a), LDL-C, and ApoB, as well as improvements in ANTICIPATE-NASH risk scores for patients with compensated MASH cirrhosis.
Key figures
- Drug Name
- Rezdiffra (resmetirom)
- Phase Of Trial
- Phase 3
- Liver stiffness improvement dose
- 100mg
- Liver stiffness improvement rate
- 91%
- Liver stiffness improvement timeframe
- one year
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.